New drug could extend relief for rare nerve disorder
NCT ID NCT06537999
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 34 times
Summary
This study tests a new drug called DNTH103 in 36 adults with multifocal motor neuropathy, a rare condition that causes muscle weakness. The goal is to see if the drug is safe and can delay the need for standard immunoglobulin therapy. Participants will receive either the drug or a placebo, and researchers will monitor side effects and how long it takes for symptoms to worsen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIFOCAL MOTOR NEUROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Study Site
RECRUITINGScottsdale, Arizona, 85251, United States
-
Clinical Study Site
RECRUITINGLos Angeles, California, 90048, United States
-
Clinical Study Site
RECRUITINGBradenton, Florida, 34205, United States
-
Clinical Study Site
RECRUITINGTampa, Florida, 33620, United States
-
Clinical Study Site
RECRUITINGHonolulu, Hawaii, 96817, United States
-
Clinical Study Site
RECRUITINGKansas City, Kansas, 66103, United States
-
Clinical Study Site
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Clinical Study Site
RECRUITINGCincinnati, Ohio, 45219, United States
-
Clinical Study Site
RECRUITINGColumbus, Ohio, 43210, United States
-
Clinical Study Site
RECRUITINGHouston, Texas, 77030, United States
-
Clinical Study Site
RECRUITINGAarhus, 8200, Denmark
-
Clinical Study Site
RECRUITINGCopenhagen, 1172, Denmark
-
Clinical Study Site
RECRUITINGMarseille, 13005, France
-
Clinical Study Site
RECRUITINGParis, 94000, France
-
Clinical Study Site
RECRUITINGRome, 00189, Italy
-
Clinical Study Site
RECRUITINGAmsterdam, 1105, Netherlands
-
Clinical Study Site
RECRUITINGUtrecht, Netherlands
-
Clinical Study Site
RECRUITINGSkopje, North Macedonia
-
Clinical Study Site
RECRUITINGBydgoszcz, 85-090, Poland
-
Clinical Study Site
RECRUITINGKatowice, 40-689, Poland
-
Clinical Study Site
RECRUITINGKrakow, 30-688, Poland
-
Clinical Study Site
RECRUITINGKrakow, 31-202, Poland
-
Clinical Study Site
RECRUITINGBelgrade, 11000, Serbia
-
Clinical Study Site
RECRUITINGBarcelona, 08035, Spain
-
Clinical Study Site
RECRUITINGLondon, England, United Kingdom
-
Clinical Study Site
RECRUITINGOxford, England, United Kingdom
Conditions
Explore the condition pages connected to this study.